397 related articles for article (PubMed ID: 22840423)
1. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.
Smailhodzic D; Muether PS; Chen J; Kwestro A; Zhang AY; Omar A; Van de Ven JP; Keunen JE; Kirchhof B; Hoyng CB; Klevering BJ; Koenekoop RK; Fauser S; den Hollander AI
Ophthalmology; 2012 Nov; 119(11):2304-11. PubMed ID: 22840423
[TBL] [Abstract][Full Text] [Related]
2. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
4. Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.
Cobos E; Recalde S; Anter J; Hernandez-Sanchez M; Barreales C; Olavarrieta L; Valverde A; Suarez-Figueroa M; Cruz F; Abraldes M; Pérez-Pérez J; Fernández-Robredo P; Arias L; García-Layana A
Acta Ophthalmol; 2018 Mar; 96(2):e201-e212. PubMed ID: 28926193
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.
Piermarocchi S; Miotto S; Colavito D; Leon A; Segato T
Acta Ophthalmol; 2015 Sep; 93(6):e451-7. PubMed ID: 25402348
[TBL] [Abstract][Full Text] [Related]
6. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
McKibbin M; Ali M; Bansal S; Baxter PD; West K; Williams G; Cassidy F; Inglehearn CF
Br J Ophthalmol; 2012 Feb; 96(2):208-12. PubMed ID: 21558292
[TBL] [Abstract][Full Text] [Related]
7. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
[TBL] [Abstract][Full Text] [Related]
8. Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Hata M; Tsujikawa A; Miyake M; Yamashiro K; Ooto S; Oishi A; Nakanishi H; Takahashi A; Yoshimura N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):221-7. PubMed ID: 24961698
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.
Yamashiro K; Tomita K; Tsujikawa A; Nakata I; Akagi-Kurashige Y; Miyake M; Ooto S; Tamura H; Yoshimura N
Am J Ophthalmol; 2012 Jul; 154(1):125-36. PubMed ID: 22465368
[TBL] [Abstract][Full Text] [Related]
11. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
Hagstrom SA; Ying GS; Maguire MG; Martin DF; ; Gibson J; Lotery A; Chakravarthy U;
Ophthalmology; 2015 Aug; 122(8):1563-8. PubMed ID: 26028346
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.
Cruz-Gonzalez F; Cabrillo-Estévez L; López-Valverde G; Cieza-Borrella C; Hernández-Galilea E; González-Sarmiento R
Graefes Arch Clin Exp Ophthalmol; 2014 Mar; 252(3):469-75. PubMed ID: 24522370
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.
Shah AR; Williams S; Baumal CR; Rosner B; Duker JS; Seddon JM
Am J Ophthalmol; 2016 Mar; 163():154-166.e8. PubMed ID: 26705092
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.
Kuroda Y; Yamashiro K; Miyake M; Yoshikawa M; Nakanishi H; Oishi A; Tamura H; Ooto S; Tsujikawa A; Yoshimura N
Ophthalmology; 2015 Nov; 122(11):2303-10. PubMed ID: 26271842
[TBL] [Abstract][Full Text] [Related]
15. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
[TBL] [Abstract][Full Text] [Related]
16. The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.
Dikmetas O; Kadayıfcılar S; Eldem B
Mol Vis; 2013; 19():2571-8. PubMed ID: 24367156
[TBL] [Abstract][Full Text] [Related]
17. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
Lin LY; Zhou Q; Hagstrom S; Maguire MG; Daniel E; Grunwald JE; Martin DF; Ying GS;
JAMA Ophthalmol; 2018 Jun; 136(6):682-688. PubMed ID: 29801032
[TBL] [Abstract][Full Text] [Related]
18. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
[TBL] [Abstract][Full Text] [Related]
19. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
Valverde-Megías A; Veganzones-de-Castro S; Donate-López J; Maestro-de-Las-Casas ML; Megías-Fresno A; García-Feijoo J
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2091-2098. PubMed ID: 28744656
[TBL] [Abstract][Full Text] [Related]
20. Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration.
Park UC; Shin JY; Kim SJ; Shin ES; Lee JE; McCarthy LC; Newcombe PJ; Xu CF; Chung H; Yu HG
Retina; 2014 Feb; 34(2):288-97. PubMed ID: 23842101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
